---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000152"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:16:26.236111+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q2 revenue $338M beats guidance; net loss $261M on $307M impairment; FY guidance cut

## Summary
- Q2 total revenues $338M vs. prior guidance range; net loss $261M ($5.15 diluted EPS) on $307M CDMO asset impairment.
- Adjusted EBITDA of $56M improved from $(29)M a year ago; adjusted net loss per share $1.06.
- FY 2023 revenue guidance revised to $1.0-1.1B (from $1.1-1.2B); adjusted EBITDA cut to $50-100M from $100-150M.
- CEO transition: Haywood Miller appointed interim CEO after Robert Kramer retired; FDA approved CYFENDUS anthrax vaccine.
- Sale of travel health business to Bavarian Nordic for up to $380M closed; 10-year BARDA contract for Ebanga Ebola treatment.

## SEC filing metadata
- accession: 0001367644-23-000152
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/0001367644-23-000152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/ebs-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000152
- JSON: https://secwatch.observer/filing/0001367644-23-000152.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000152.txt

## Key facts
- Earnings Releases
  Emergent BioSolutions Inc. reported the second quarter ended June 30, 2023 results: revenue Total Revenues $337.9, net income Net Loss $(261.3), EPS Net Loss per Diluted Share $(5.15).
  - Period: the second quarter ended June 30, 2023
  - Revenue: Total Revenues $337.9
  - Net income: Net Loss $(261.3)
  - EPS: Net Loss per Diluted Share $(5.15)
  - Result: reported results
  source text: by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EMERGENT BIOSO LUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2023 • Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M • Updates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues GAITHERSBURG,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/0001367644-23-000152-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.